This is the second part of a 2-part Infertility series. Read Part 1: The diagnosis of the infertile couple
Infertility treatment begins with shared decision-making with the couple. Besides the usual risks, benefits, and alternatives, the couples desire for a biologic child, their resources, and their insurance coverage will govern subsequent therapy.
Accurate diagnosis from a basic infertility evaluation often results in an easy therapeutic recommendation.
Based on their diagnosis, a couple may be offered a variety of treatments: often simple, sometimes very complex. Genetic testing of couples or their embryos will also provide additional opportunities in family building. Donor gametes, donor embryos, and adoption are often the most cost-effective route to having a child.
Clomiphene citrate is a synthetic estrogen receptor modulator. By blocking the estrogen receptor at the level of the hypothalamus and pituitary, the negative feedback of estrogen is eschewed and gonadotropin-releasing hormone (GNRH) pulses increase follicle-stimulating hormone (FSH) and luteinizing hormone (LH) production.1
These elevated gonadotropins stimulate early follicle development, increase estradiol production, and mature the oocyte. Clomiphene is most often administered as a daily oral dose for 5 days in the early follicular phase (eg, beginning between day 3 and day 5 of the menstrual cycle), beginning at 50 mg/day.
Clomiphene citrate causes FSH and LH to rise; after discontinuation, gonadotropins fall and allow the normal estrogen feedback of a developing follicle to return. Thus, when the oocyte is mature, an LH surge is triggered by the ovary, or an exogenous human chorionic gonadotropin hormone (HcG) trigger can be administered, and ovulation ensues.
Adverse effects (AEs) of clomiphene citrate include hot flashes, thickened cervical mucus, vaginal dryness, scotomata, pelvic heaviness, and headaches.1 Hyperstimulation of the ovaries is rare. Because clomiphene citrate may cause thickened cervical mucus, it is often used in combination with intrauterine insemination, especially in treatment of unexplained infertility.2
Aromatase inhibitors act in a similar fashion to clomiphene citrate, although by a different mechanism.
These medications block aromatase, the enzyme which converts androgens to estrogens; estrogen is decreased to menopausal levels. The low concentration of estrogen results in increased GNRH pulses and stimulates gonadotropin release from the pituitary.
Aromatase inhibitors are given orally, starting at 2.5 mg per day from day 3 to 8 of the cycle. AEs include hot flashes, vaginal dryness, nausea, muscle aches, and headaches. Data from meta-analyses, registry studies, and retrospective cohort studies do not appear to suggest increased risk of birth defects with either clomiphene citrate or letrozole.3-10
Patients treated with clomiphene citrate or aromatase inhibitors may use an ovulation predictor kit to measure the LH surge and time their intercourse accordingly. Ovulation occurs an average of 7 days after discontinuation of clomiphene citrate and approximately 34 to 40 hours after detection of the LH surge.
Thus, patients may start testing their urine with an ovulation predictor kit on day 11 of their cycle and have intercourse on the day of the surge and the day after. Both clomiphene citrate and aromatase inhibitors have a multiple pregnancy rate of less than 10%, the majority of which are twin pregnancies,11 compared with 3% of the general population.
Gonadotropins (LH and FSH) directly stimulate the ovarian follicles and have been used in the treatment of anovulation related to eugonadotropic hypogonadism (eg, polycystic ovary syndrome), when clomiphene citrate or aromatase inhibitors fail, as well as for women with hypogonadotropic hypogonadism who will typically not respond to clomiphene or letrozole.
Estrogen concentrations are stimulated to much higher than physiologic concentrations and thus inhibit the natural ovulatory LH surge; thus, the LH surge must be exogenously administered and is done so by treating with HcG, which has LH activity.
Gonadotropin administration should be performed only under the supervision of a reproductive endocrinologist. Administration must be monitored by frequent estradiol measurement and ultrasonography of the ovaries.12 Multiple pregnancy rates can be in excess of 25% per cycle with 3% to 5% higher-order multiple pregnancy rates.
Another serious consequence of gonadotropin treatment is ovarian hyperstimulation syndrome (OHSS), resulting in ascites, pleural effusion, hyponatremia, pulmonary edema,13,14 and vascular depletion, with the resultant hemoconcentration leading to decreased renal perfusion and pulmonary embolism.
In light of the high multiple pregnancy rate as well as the need for stringent monitoring and cycle cancellation,5 gonadotropin therapy for anovulation related to eugonadotropic hypogonadism is generally discouraged.
It is important to note that once a patient is ovulating, she has the same chance of conceiving that fertile patients of similar age have, unless another infertility factor is present.
Therefore, after 4 to 6 ovulatory cycles without pregnancy in an anovulatory patient, the patient should be evaluated for other causes of infertility, if a workup has not already been completed.15
Intrauterine insemination (IUI) is used in the treatment of mild male factor infertility, cervical factor infertility, and, along with ovarian stimulation, in the treatment of unexplained infertility. This requires serial dilution of the ejaculate,16 centrifugation, and reconstitution with media.
The washed, concentrated sperm is placed into the uterus with a catheter 24 to 36 hours after an endogenous LH surge or the exogenous ovulation trigger. The sperm will be waiting in the Fallopian tube to fertilize the oocyte after ovulation.
For unexplained infertility in the absence of male factor, IUI alone does not increase pregnancy rates over expectant management; therefore, IUI should be utilized in combination with OS in these instances.17
If severe male factor infertility exists (eg, less than 4 million total sperm, or the strict morphology reveals less than 4% normal forms), the pregnancy rate with in vitro fertilization (IVF) is higher than with IUI.18
Ovarian stimulation (OS) may be used to treat unexplained infertility, male factor infertility, or hypogonadotropic hypogonadism, and may be performed with clomiphene citrate, aromatase inhibitors, or gonadotropins. The premise of OS is to allow for 2 or 3 oocytes to be ovulated and increase the statistical change of conception that might occur in any 1 cycle.
Pregnancy rates with OS depend on the diagnosis, choice of therapy, sperm viability, and ovarian response. OS in combination with IUI is largely used in the treatment of unexplained infertility or male factor infertility; particularly for unexplained infertility, neither clomiphene nor letrozole is more effective than expectant management when combined with timed intercourse alone.17 Pregnancy rates with OS-IUI depend on the diagnosis, sperm viability, and ovarian response.
With respect to OS with gonadotropins, the Fast Track and Standard Treatment Trial randomized women aged less than 40 years with unexplained infertility to treatment with clomiphene-IUI followed, if unsuccessful, by (1) gonadotropins-IUI or (2) IVF; results showed that the time to pregnancy was significantly shorter in the clomiphene to IVF group.19
Therefore, in most cases, it is generally recommended that unsuccessful trials of OS with oral medications be followed by IVF rather than gonadotropins. Additionally, multiple pregnancies, as well as OHSS, represent serious consequences of OS with gonadotropins, and their use to treat unexplained infertility is not recommended.17
Infertile women may be at an increased risk of invasive ovarian, endometrial, and breast cancer, but fertility drugs do not appear to increase this risk significantly.20,21
Small cohort studies suggest that infertility medications may increase theriskof borderline ovarian cancer slightly in infertile women treated with infertility drugs, but the absolute risk is small. However, it appears that this risk does not occur unless clomiphene is given for an extended time, and it has not been shown with aromatase inhibitors.22
In vitro fertilization (IVF) initially used for the treatment of tubal factor infertility in 1978, has been extended to treat a variety of causes of infertility; IVF is also used by noninfertile individuals pursuing fertility preservation.
Indeed, IVF allows women without oocytes or a uterus and men without sperm in the ejaculate to have a biological child. IVF is indicated in cases of severe oligospermia or azoospermia, untreated tubal factor, or infertility in women 40 years and older, and it may also be utilized in women with endometriosis, anovulation, or unexplained infertility when ovulation induction and IUI have been unsuccessful. IVF is also utilized when genetic screening of embryos is planned.
IVF protocols vary depending on the indication, patient age, treatment history, and other considerations.
A typical IVF cycle involves, first, ovulation induction to stimulate multiple ovarian follicles, followed by oocyte aspiration using a transvaginal ultrasound-guided needle. Collected oocytes are fertilized in vitroby mixing them with spermatozoa (IVF) or by injecting selected spermatozoa directly into the oocyte cytoplasm (intracytoplasmic sperm injection).
Embryos are cultured under carefully controlled conditions, optimizing oxygen concentration, embryo culture media, and other modifications to promote the development of high-quality embryos.
The embryos are then transferred into the uterus through a catheter under ultrasound guidance. In the case of severe male factor infertility, sperm retrieval from the epididymis or testis may also be performed. Embryos not transferred may be cryopreserved to transfer in a later cycle (frozen embryo transfer).
Preimplantation genetic testing (PGT) is a procedure in which cultured embryos can be biopsied and tested in order to select the most appropriate embryos for transfer.
Prior to transfer, PGT can be used to screen for euploid embryos for transfer (PGT-aneuploid [PGT-A]); however, specific groups of infertility patients most likely to benefit from PGT-A have not been clearly defined. PGT may also be utilized to identify embryos with a single gene disorder (PGT-monogenic or preimplantation genetic diagnosis); this would be used, for example, if both partners are carriers for the same autosomal recessive condition, such as cystic fibrosis.
Donor gametes may be considered when either partner has severe defects in gamete quality or quantity. For males, such situations may include severe oligospermia, azoospermia, failure of fertilization in prior IVF cycles, ejaculatory dysfunction, or other severe male factor infertility (ie, after gonadotoxic chemotherapy).
Donor oocytes or embryos may be used when a womans oocyte reserve is low (ie, advanced reproductive age or diminished ovarian reserve) or oocyte quality is poor, when multiple attempts at IVF with her own oocytes have failed, or when a condition such as premature ovarian insufficiency makes the likelihood of conceiving with her own gametes extremely low.
Donor gametes may also be utilized when either partner has a significant genetic defect, or if there is a family history of a genetic condition for which carrier status cannot be determined.
Females without male partners, same-sex couples, or males without female partners may also utilize donor gametes, either anonymously from donor gamete banks or known donors.23
A gestational carrier (GC) is defined as a woman who carries a pregnancy and is not sexually intimate with the genetic parents or gamete donors.24
A GC may be used when a medical condition prevents a woman from carrying a pregnancy or when she has a congenital or surgical absence of a uterus. A GC may also be indicated if a pregnancy would pose significant risk to a womans health or life, or if there is a biological inability to carry a pregnancy, as with single males or gay male couples.
Lastly, uterine transplant is an emerging option for individuals without a uterus; it is currently available only in the setting of clinical research trials.25
Although legal adoption has allowed couples to build a family for more than a century, modern technology now allows for effective therapy for infertility in many cases, guided by accurate diagnosis and shared decision-making.
The basic evaluation of an infertile couple has been supplemented with an evaluation of related health issues, as our knowledge has advanced to include surveillance beyond the reproductive system (Table).
The primary care practitioner is vital in not only initiating the evaluation, surveying for related health problems, and referring to specialty care, but also longitudinally, following patients for possible disease processes harbingered by infertility.
About the Authors
DR. KALLEN is an assistant professor of Obstetrics, Gynecology, and Reproductive Sciences in the Division of Reproductive Endocrinology and Infertility within the Department of Obstetrics, Gynecology, and Reproductive Sciences at Yale School of Medicine, Yale University.
DR. CARSON is a professor of Obstetrics, Gynecology, and Reproductive Sciences in the Division Chief, Division of Reproductive Endocrinology and Infertility within the Department of Obstetrics, Gynecology, and Reproductive Sciences at Yale School of Medicine, Yale University.
Continue reading here:
Treatment of the infertile couple - Contemporary Obgyn
- EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi and Submits Market... - October 22nd, 2020
- Male Hypogonadism Therapy Market is Booming Worldwide By Top Key Players: Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva,... - October 17th, 2020
- Share tips of the week - MoneyWeek - October 17th, 2020
- Harvard Study Shows That Flavonoids Could Prevent Erectile Dysfunction - Gilmore Health News - October 17th, 2020
- Latest Report By QYResearch on Hormone Replacement Therapy (HRT) Market Trend, Overview, Competitor Analysis, Growth by 2026 - Weekly Wall - October 9th, 2020
- Covid-19 could lower testosterone levels and libido in men - heres what the new study found - Derry Journal - October 9th, 2020
- Sperm Take Up to 3 Years to Recover After Anabolic Steroids - Medscape - October 3rd, 2020
- Covid-19 could lower testosterone levels and libido in men - heres what the new study found - Shields Gazette - October 3rd, 2020
- Impact of COVID-19 on Global Testosterone undecanoate Market Size, Share, Segmentations and Forecast 2025 by Industry Key Players, Solutions and... - October 3rd, 2020
- Consumers Opting For To Help The Male Hypogonadism Market Cross US$ 3,300 Mn Between 2026 - industrytoday.co.uk - September 25th, 2020
- Testosterone boosters: Uses and effectiveness - Medical News Today - September 22nd, 2020
- Aytu BioScience to Report Fourth Quarter FY 2020 Results and Business Update on Thursday, September 24, 2020 - Yahoo Finance - September 22nd, 2020
- Male Hypogonadism Therapy Market with Future Prospects, Key Player SWOT Analysi - News by aeresearch - September 11th, 2020
- Hypergonadism: Symptoms, Causes, Treatment, and More - September 11th, 2020
- Male Hypogonadism Market To Witness A CAGR Of 3.7% Between 2026 - Bulletin Line - September 7th, 2020
- Covid-19 Impact on Global Testosterone Cypionate Market by Product Type, With Production, Revenue, Price, Industry Share and Growth Rate, Analysis... - September 7th, 2020
- Vogelzang Discusses Treatment Choices for mCRPC in the Frontline and Beyond - Targeted Oncology - August 31st, 2020
- Hormone Replacement Therapy Market: Rising incidences of hormonal imbalance disorders is the primary drivers of this market - BioSpace - August 31st, 2020
- International honour for Sheffield pioneer of therapy for children with chronic hormone deficiency - indiaeducationdiary.in - August 29th, 2020
- LPCN: Tlando: Target Action Date This Friday - Zacks Small Cap Research - August 25th, 2020
- UB diabetes expert's research shows testosterone therapy can lead to remission in men with Type 2 diabetes - UB News Center - July 30th, 2020
- Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration - Yahoo Finance - July 30th, 2020
- What is Male Menopause? Heres everything you need to know about andropause - PINKVILLA - July 25th, 2020
- Impact of Covid-19 on Male Hypogonadism market 2020 | What are the key challenges to the Industry growth? - Bulletin Line - July 25th, 2020
- Male Hypogonadism Market expected to Witness a Sustainable Growth over 2017 - 2026 - Techinfeed - July 7th, 2020
- Steroids Know Factors Driving The Market to Record Growth - Daily Research Chronicles - July 7th, 2020
- Male Hypogonadism Market and Demand for COVID-19 Market Growth Projected to Amplify By 2027 | Eli Lilly and Company, Endo International, Merck &... - July 4th, 2020
- No fountain of youth: Just because theres a way to boost testosterone doesnt mean you should, experts warn - Gadsden Times - June 25th, 2020
- QOL and body composition benefits seen with novel oral T treatment - Urology Times - June 15th, 2020
- Novel oral testosterone therapy shows liver health benefits - Urology Times - June 15th, 2020
- Male Hypogonadism Therapy Market Business Analysis 2020 by Leading Industrial Source, Statistics, Gross Margin, Upstream Analysis, Downstream Analysis... - June 15th, 2020
- Male Hypogonadism Market Future Growth by In Depth Industry Analysis, Size, Trends and Forecast to 2026 - Cole of Duty - June 11th, 2020
- COVID-19 Update: Global Transdermal Testosterone Market is Expected to Grow at a Healthy CAGR with Top players: AbbVie, Teva, Perrigo, Endo... - June 11th, 2020
- Male Hypogonadism Therapy Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026 - Cole of Duty - June 8th, 2020
- Male Hypogonadism Market to Witness a Healthy YoY Growth during 2017 2026 - Personal Injury Bureau UK - June 8th, 2020
- Jacobs School appoints new chair of Obstetrics and Gynecology - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter - June 8th, 2020
- Transdermal Testosterone Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026| - Jewish Life News - May 31st, 2020
- Male Hypogonadism Market Future Aspect Analysis and Current Trends by 2017 to 2025 - 3rd Watch News - May 24th, 2020
- Marius Pharmaceuticals Announces Issuance of Two Key Patents Protecting its Proprietary Oral Testosterone Therapy - Yahoo Finance - May 24th, 2020
- The Economic Impact of Coronavirus on Male Hypogonadism Market Analysis and Value Forecast Snapshot by End-use Industry 2019-2021 - 3rd Watch News - May 24th, 2020
- Men with Hypogonadism Leading to Low Testosterone Levels are More Likely to Die From the Coronavirus, Study Fi - Science Times - May 17th, 2020
- COVID-19 Testing Continues to Lift Aytu BioScience Stock - 24/7 Wall St. - May 17th, 2020
- Male Hypogonadism Therapy Market 2020 | Growth Drivers, Challenges, Trends, Market Dynamics and Forecast to 2026 - Cole of Duty - May 9th, 2020
- The impact of the coronavirus on the Male Hypogonadism Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 20582019-2019 - Jewish Life News - May 5th, 2020
- How Coronavirus Pandemic Will Impact Male Hypogonadism Market Poised for Steady Growth in the Future - Latest Herald - May 5th, 2020
- Male Hypogonadism Market Increasing Demand with Leading Key Players, Revenue Growth Analysis and Industry Share Price, Forecast 2025 - amitnetserver - May 5th, 2020
- Global trade impact of the Coronavirus Male Hypogonadism Market Shares, Strategies and Forecast Worldwide, 2019-2026 - Cole of Duty - May 5th, 2020
- Addressing the potential impact of coronavirus disease (COVID-19) on Male Hypogonadism Therapy Market : Future Growth and Challenges Analyzed Aminet... - May 3rd, 2020
- Male Hypogonadism Market Key Players, Product and Production Information analys - News by aeresearch - April 30th, 2020
- Hormone Replacement Therapy (HRT) Market Growth Is Skyrocketing Beyond Predictions - Express Journal - April 30th, 2020
- Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market to Surpass US$ 99,772.2 Million by 2027 - CMI - GlobeNewswire - April 28th, 2020
- The impact of the coronavirus on the Male Hypogonadism Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 20682019-2019 - Jewish Life News - April 25th, 2020
- The impact of the coronavirus on the Male Hypogonadism Market Solid Analyzed Segmentation, Demand, Recent Share Estimation and Growth Prospects by... - April 24th, 2020
- Male Hypogonadism Therapy Market Analysis by Size, Share, Top Key Manufacturers, Demand Overview, Regional Outlook And Growth Forecast to 2026 Cole... - April 24th, 2020
- Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market to Surpass US$ 99,772.2 Million by 2027 - CMI - Yahoo Finance - April 24th, 2020
- Global Male Hypogonadism Market 2019 Comprehensive Study with On-Going Trends, Majors Players and Forecast 2025 - Northwest Trail - April 22nd, 2020
- Low T Center Is Committed To Meeting The Needs Of Colorado Patients During The COVID-19 Emergency - The Grand Junction Daily Sentinel - April 18th, 2020
- Aytu BioScience Confirms Export and Incoming Delivery of COVID-19 IgG/IgM Rapid Tests - Yahoo Finance - April 18th, 2020
- What is testosterone replacement therapy, and do you need it - KTAR.com - March 31st, 2020
- Alcohol Consumption Linked to Lower Bone Formation Markers in Patients With HIV - Infectious Disease Advisor - March 23rd, 2020
- Aytu BioScience Expands Its Distribution Rights for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test to Canada and Mexico - Yahoo Finance - March 20th, 2020
- FDA: Thousands of Deaths Associated With Drugs Given to 'Trans' Children - Catholic Citizens of Illinois - March 20th, 2020
- Aytu BioScience Announces Acceleration of U.S. Availability of COVID-19 IgG/IgM Rapid Test Based on Updated FDA Policy - Yahoo Finance - March 18th, 2020
- CLARUS THERAPEUTICS ANNOUNCES FINANCING TO SUPPORT THE COMMERCIAL LAUNCH AND AVAILABILITY OF JATENZO (TESTOSTERONE UNDECANOATE) CAPSULES, CIII FOR THE... - March 16th, 2020
- Aytu BioScience's Coronavirus Rapid Test Featured on NBC and Fox News (VIDEOS): ''Englewood Company Says It Can Get COVID-19 Test Results in 2-10... - March 16th, 2020
- Long-term Opioid Use in Men Linked to Hypogonadism - Medscape - March 15th, 2020
- Alcohol Consumption Linked to Lower Bone Formation Markers in Patients With HIV - Endocrinology Advisor - March 15th, 2020
- Jatenzo, an Oral Testosterone Replacement Therapy, Now Available - Renal and Urology News - February 24th, 2020
- Clarus Therapeutics Lauches JATENZO - Oral Testosterone Replacement Therapy - MedicalResearch.com - February 24th, 2020
- 6 Serious Health Conditions Linked To Erectile Dysfunction - The African Exponent - February 19th, 2020
- Jatenzo, an Oral Testosterone Replacement Therapy, Now Available - Monthly Prescribing Reference - February 12th, 2020
- Male Hypogonadism Therapy Market Size Current and Future Industry Trends, 2020- - News by aeresearch - February 12th, 2020
- Male Hypogonadism to Witness Growth Acceleration During 2018 2028 - Redhill Local Councillors - February 12th, 2020
- Global Male Hypogonadism Market 2019 Comprehensive Study with On-Going Trends, Majors Players and Forecast 2025 - Global Newspaper - February 5th, 2020
- Mineral and Hormonal Dysfunction Associated With Lower BMD in Thalassemia Major - Endocrinology Advisor - February 3rd, 2020
- The Rape Case Against Nithyananda Should Be Dropped If They Had Sex, She Obviously Wanted It! - Frank Report - February 3rd, 2020
- Mineral, Hormonal Dysfunction Associated With Lower BMD in Thalassemia Major - Rheumatology Advisor - January 31st, 2020
- Global Hormone Replacement Therapy (HRT) Market: Industry Analysis and Forecast (2020-2026) - NY Telecast 99 - January 31st, 2020
- Galactorrhea affects 24% women, not linked to breast cancer - The Sentinel Assam - January 31st, 2020
- Global Hormone Replacement Therapy Market 2020 Company Business Overview, Sales, Revenue and Gross Margin(2013-2020), Recent Development 2025 -... - January 31st, 2020